ArticleBMC cancer2026

Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.

Li Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.